Thus, it is amenable to develop a radiolabeled tryptophan to monitor in vivo expression and activity of IDO, LAT1, and TPH1 as well as to assess therapeutic response after selective inhibitors of IDO, LAT1, and TPH1 in cancer treatments. Here, LAT is linked to cancer.